

THESE FINANCIAL STATEMENTS FOR JUSHI HOLDINGS INC. ARE ALSO INCLUDED IN THE FORM 10-Q FOR

THE QUARTERLY PERIOD ENDED JUNE 30, 2023, FILED ON SEDAR IN ITS ENTIRETY

Table of Contents

For the quarterly period ended June 30, 2023

Part I	FINANCIAL INFORMATION	Page
Item 1	Financial Statements	
	Condensed Consolidated Balance Sheets	1
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)	2
	Unaudited Condensed Consolidated Statements of Changes in Equity	3
	Unaudited Condensed Consolidated Statements of Cash Flows	4
	Notes to the Unaudited Condensed Consolidated Financial Statements	6

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-O (this "report") may contain "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws, including Canadian securities legislation and United States ("U.S.") securities legislation (collectively, "forward-looking information") which are based upon the Company's current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this report that address activities, events or developments that Jushi expects or anticipates will or may occur in the future constitutes forward-looking information. Forward-looking information is often identified by the words. "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes, among others, information regarding: future business strategy, competitive strengths, goals, expansion and growth of Jushi's business, operations and plans, including new revenue streams, the integration and benefits of recently acquired businesses or assets, roll out of new operations, the implementation by Jushi of certain product lines, implementation of certain research and development, the application for additional licenses and the grant of licenses that will be or have been applied for, the expansion or construction of certain facilities, the reduction in the number of our employees, the expansion into additional U.S. and international markets, any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which Jushi operates; expectations for other economic, business, regulatory and/or competitive factors related to Jushi or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of the management of Jushi at the time they were provided or made and such information involves known and unknown risks, uncertainties, including our ability to continue as a going concern, and other factors that may cause the actual results, level of activity, performance or achievements of Jushi, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to the economy generally; risks related to inflation, the rising cost of capital, and stock market instability; risks relating to pandemics and forces of nature; risks related to contracts with third party service providers; risks related to the enforceability of contracts; the limited operating history of Jushi's history of operating losses and negative operating cash flows; reliance on the expertise and judgment of senior management of Jushi; risks inherent in an agricultural business; risks related to coinvestment with parties with different interests to Jushi; risks related to proprietary intellectual property and potential infringement by third parties; risks relating to the Company's recent debt financing and other financing activities including increased leverage and issuing additional equity securities; risks relating to the management of growth; costs associated with Jushi being a publicly-traded company and a U.S. and Canadian filer; increasing competition in the industry; risks associated with cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; reliance on manufacturers and contractors; risks of supply shortages or supply chain disruptions; cybersecurity risks; constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcing judgments and effecting service outside of Canada; risks related to completed, pending or future acquisitions or dispositions, including potential future impairment of goodwill or intangibles acquired and/or post-closing disputes; sales of a significant amount of shares by existing shareholders; the limited market for securities of the Company; risks related to the continued performance of existing operations in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania, and Virginia; risks related to the anticipated openings of additional dispensaries or relocation of existing dispensaries; risks relating to the expansion and optimization of the grower-processor in Pennsylvania, the vertically integrated facilities in Virginia and Massachusetts and the facility in Nevada; risks related to opening new facilities, which is subject to licensing approval; limited research and data relating to cannabis; risks related to challenges from governmental authorities of positions the Company has taken with respect to tax credits; and risks related to the Company's critical accounting policies and estimates. Refer to Part I - Item 1A. Risk Factors in Jushi's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on April 18, 2023 for more information

Although Jushi has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on the forward-looking information contained in this report or other forward-looking statements made by Jushi. Forward-looking information is provided and made as of the date of this Quarterly Report on Form 10-Q and Jushi does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law.

Unless the context requires otherwise, references in this report to "Jushi," "Company," "we," "us" and "our" refer to Jushi Holdings Inc. and our subsidiaries.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

JUSHI HOLDINGS INC. CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars, except share amounts)

		June 30, 2023 (unaudited)	December 31, 2022		
ASSETS					
CURRENT ASSETS:					
Cash and cash equivalents	\$	26,784	\$	26,196	
Restricted cash - current		3,128		_	
Accounts receivable, net		5,323		4,809	
Inventory, net		40,780		35,089	
Prepaid expenses and other current assets		14,274		3,957	
Total current assets		90,289		70,051	
NON-CURRENT ASSETS:					
Property, plant and equipment, net		169,825		177,755	
Right-of-use assets - finance leases		65,245		114,021	
Other intangible assets, net		98,471		100,082	
Goodwill		38,239		38,239	
Other assets		37,271		28,243	
Restricted cash - non-current		2,150		950	
Total non-current assets		411,201		459,290	
Total assets	\$	501,490	\$	529,341	
LIABILITIES AND EQUITY					
CURRENT LIABILITIES:					
Accounts payable	\$	21,608	\$	21,313	
Accrued expenses and other current liabilities		49,857		46,329	
Income tax payable		32,575		19,921	
Debt, net - current portion (including related party principal amounts of \$3,254 and \$3,189 as of June 30, 2023 and December 31, 2022, respectively)		14,791		8,704	
Finance lease obligations - current		8,786		11,361	
Total current liabilities		127,617		107,628	
NON-CURRENT LIABILITIES:					
Debt, net - non-current (including related party principal amounts of \$18,526 and \$17,491 as of June 30, 2023 and December 31, 2022, respectively)		198,641		180,558	
Finance lease obligations - non-current		52,699		102,375	
Derivative liabilities		3,107		14,134	
Income tax liabilities - non-current		60,492		57,200	
Other liabilities - non-current		31,454		21,555	
Total non-current liabilities		346,393		375,822	
Total liabilities		474,010		483,450	
COMMITMENTS AND CONTINGENCIES (Note 18)					
EQUITY:					
Common stock, no par value: authorized shares - unlimited; issued and outstanding shares - 196,633,371 and 196,686,372 Subordinate Voting Shares as of June 30, 2023 and December 31, 2022, respectively.		_		_	
Paid-in capital		500,085		492,020	
Accumulated deficit		(471,218)		(444,742)	
Total Jushi shareholders' equity		28,867		47,278	
Non-controlling interests		(1,387)		(1,387)	
Total equity		27,480		45,891	
Total liabilities and equity	\$	501,490	\$	529,341	
	_	201,170	_	027,511	

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars, except share and per share amounts)

	T	Three Months Ended June 30,		Six Months E		Ended June 30,		
		2023	2	2022		2023		2022
REVENUE, NET	\$	66,425	\$	72,757	\$	136,298	\$	134,645
COST OF GOODS SOLD		(35,871)		(46,089)		(75,803)		(88,865)
GROSS PROFIT		30,554		26,668		60,495		45,780
OPERATING EXPENSES		27,154		38,745		59,606		76,458
Of Electrical Extension		27,101		30,713		27,000		70,130
INCOME (LOSS) FROM OPERATIONS		3,400		(12,077)		889		(30,678)
OTHER INCOME (EXPENSE):								
Interest expense, net		(9,790)		(10,947)		(18,310)		(21,063)
Fair value gains on derivatives		1,090		42,572		9,120		56,881
Other, net		(190)		228		519		(70)
Total other income (expense), net		(8,890)		31,853		(8,671)		35,748
INCOME (LOSS) BEFORE INCOME TAX		(5,490)		19,776		(7,782)		5,070
Income tax expense		(8,546)		(7,710)		(18,694)		(12,761)
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)		(14,036)		12,066		(26,476)		(7,691)
Less: net loss attributable to non-controlling interests		_		_		_		_
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO JUSHI SHAREHOLDERS	\$	(14,036)	\$	12,066	\$	(26,476)	\$	(7,691)
EARNINGS (LOSS) PER SHARE ATTRIBUTABLE TO JUSHI SHAREHOLDERS - BASIC	\$	(0.07)	\$	0.06	\$	(0.14)	\$	(0.04)
Weighted average shares outstanding - basic	19	4,756,391	190,	870,572	19	4,405,562	18	7,147,856
EARNINGS (LOSS) PER SHARE ATTRIBUTABLE TO JUSHI SHAREHOLDERS - DILUTED	\$	(0.07)	\$	(0.15)	\$	(0.14)	\$	(0.31)
Weighted average shares outstanding - diluted	19	4,756,391	205,	697,153	19	4,405,562	20	8,038,283

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(In thousands of U.S. dollars, except share amounts)

aid-In apital	A	ccumulated Deficit	otal Jushi areholders' Equity	Non- ontrolling nterests	To	otal Equity
492,020	\$	(444,742)	\$ 47,278	\$ (1,387)	\$	45,891
_		_	_	_		_

	Subordinate Voting Shares	Paid-In Capital	Accumulated Deficit	Shareholders' Equity	Controlling Interests	Total Equity
Balances - January 1, 2023	196,686,372	\$ 492,020	\$ (444,742)	\$ 47,278	\$ (1,387)	\$ 45,891
Shares canceled upon forfeiture of restricted stock, net of restricted stock grants	(53,001)	_	_	_	_	_
Share-based compensation (including related parties)	_	2,311	. —	2,311	_	2,311
Net loss		_	(12,440)	(12,440)		(12,440)
Balances - March 31, 2023	196,633,371	494,331	(457,182)	37,149	(1,387)	35,762
Modification and reclassification of warrants		3,39	_	3,391	_	3,391
Share-based compensation (including related parties)	_	2,363	_	2,363	_	2,363
Net loss		_	(14,036)	(14,036)		(14,036)
Balances - June 30, 2023	196,633,371	\$ 500,085	\$ (471,218)	\$ 28,867	\$ (1,387)	\$ 27,480

Six Months Ended June 30, 2023

	Six Months Ended June 30, 2022						
	Subordinate Voting Shares		Paid-In Capital	Accumulated Deficit	Total Jushi Shareholders' Equity	Non- Controlling Interests	Total Equity
Balances - January 1, 2022	182,707,359	\$	424,788	\$ (242,418)	\$ 182,370	\$ (1,387)	\$ 180,983
Private placement offerings	3,717,392		13,680	_	13,680	_	13,680
Shares issued for Apothecarium acquisition	527,704		1,594	_	1,594	_	1,594
Shares issued for restricted stock grants	5,952		_	_	_	_	
Shares issued upon exercise of warrants	2,676,303		9,693	_	9,693	_	9,693
Shares issued upon exercise of stock options	93,915		_	_	_	_	
Share-based compensation (including related parties)	_		6,964	_	6,964	_	6,964
Net loss				(19,757)	(19,757)		(19,757
Balances - March 31, 2022	189,728,625		456,719	(262,175)	194,544	(1,387)	193,157
Shares issued for NuLeaf acquisition	4,662,384		13,573		13,573	_	13,573
Shares issued for services received	101,082		294	_	294	_	294
Shares issued upon exercise of warrants	167,560		322	_	322	_	322
Shares issued upon exercise of stock options	1,294		_	_	_	_	_
Shares canceled upon forfeiture of non-vested restricted stock	(7,813)		_	_	_	_	
Share-based compensation	_		4,684	_	4,684	_	4,684
Net income			_	12,066	12,066	_	12,066
Balances - June 30, 2022	194,653,132	\$	475,592	\$ (250,109)	\$ 225,483	\$ (1,387)	\$ 224,096

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

	Six Months I June 30	
	2023	2022
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net loss	\$ (26,476) \$	(7,691)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	13,964	7,603
Share-based compensation	4,674	11,648
Fair value changes in derivatives	(9,120)	(56,881)
Non-cash interest expense, including amortization of debt issuance costs	2,913	10,402
Deferred income taxes and uncertain tax positions	2,897	(2,133)
Other non-cash items, net	3,386	(60)
Changes in operating assets and liabilities:		
Accounts receivable	(764)	442
Inventory	(9,311)	7,533
Prepaid expenses and other current and non-current assets	(123)	(167)
Accounts payable, accrued expenses and other current liabilities	7,675	3,593
Net cash flows used in operating activities	(10,285)	(25,711)
CASH FLOWS FROM INVESTING ACTIVITIES:		
Payments for acquisitions, net of cash acquired	_	(20,824)
Payments for property, plant and equipment	(6,144)	(40,917)
Proceeds from sale of property, plant and equipment	916	
Net cash flows used in investing activities	(5,228)	(61,741)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from issuance of shares, net		13,680
Proceeds from exercise of warrants and options		751
Proceeds from acquisition facility		25,000
Redemption of senior notes (including related party redemptions of \$0 and \$8 for the six months ended June 30, 2023 and 2022, respectively)	_	(258)
Payments of finance leases, net of tenant allowance of \$0 and \$10,065 for the		
six months ended June 30, 2023 and 2022, respectively	(2,681)	(6,555)
Proceeds from mortgage loans	21,900	
Payments of loan financing costs	(250)	(793)
Repayments of mortgage loans	(110)	(150)
Proceeds from other financing activities	3,295	4,353
Payments of other financing activities	 (1,725)	(14)
Net cash flows provided by financing activities	20,429	36,014
Effect of currency translation on cash and cash equivalents		(238)
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	4,916	(51,676)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD	27,146	95,487
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD	\$ 32,062 \$	43,811

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(In thousands of U.S. dollars)

	Six Months End June 30,			
		2023		2022
SUPPLEMENTAL CASH FLOW INFORMATION:				
Cash paid for interest (excluding capitalized interest)	\$	14,787	\$	10,699
Cash paid for income taxes		3,145		8,542
NON-CASH INVESTING AND FINANCING ACTIVITIES:				
Capital expenditure and related accruals		2,360		7,453
Right-of-use assets obtained in exchange for new finance lease liabilities		659		4,701
Issuance of second lien notes for settlement of accrued bonus		750		_
Fair value of note obligations and warrant liabilities from acquisitions and acquisitions of non-controlling interests		_		19,782
Fair value of shares issued for acquisitions and acquisitions of non-controlling interests		_		15,167
Debt and shares issued for services received				634

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



1. NATURE OF OPERATIONS

Jushi Holdings Inc. (the "Company" or "Jushi") is incorporated under the British Columbia's Business Corporations Act. The Company is a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. As of June 30, 2023, Jushi, through its subsidiaries, owns or manages cannabis operations and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania and Virginia. The Company's head office is located at 301 Yamato Road, Suite 3250, Boca Raton, Florida 33431, United States of America, and its registered address is Suite 1700, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2X8, Canada.

The Company is listed on the Canadian Securities Exchange ("CSE") and trades its subordinate voting shares ("SVS") under the ticker symbol "JUSH", and trades on the United States Over the Counter Stock Market ("OTCQX") under the symbol "JUSHF".

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

The financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes. Actual results could differ materially from those estimates.

In the opinion of management, the unaudited consolidated financial statements include all adjustments, of a normal recurring nature, that are necessary to present fairly the financial position, results of operations and cash flows of the Company for the periods, and at the dates, presented. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022, which are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on April 18, 2023 (the "2022 Form 10-K"), and was also filed on the System for Electronic Document Analysis and Retrieval ("SEDAR") on April 18, 2023. Consolidated balance sheet information as of December 31, 2022 presented herein is derived from the Company's audited consolidated financial statements for the year ended December 31, 2022.

Going Concern and Liquidity

As reflected in the 2022 Form 10-K, the Company incurred a loss from operations of \$220,333, including non-cash impairment charges of \$159,645, and used net cash of \$21,416 for operating activities for the year ended December 31, 2022, and as of that date, the Company's current liabilities exceeded its current assets by \$37,577. Furthermore, the Company used cash of \$10,285 for operating activities for the six months ended June 30, 2023, and as of that date, the Company's current liabilities exceeded its current assets by \$37,328. Since inception, management has focused on building a diverse portfolio of assets in attractive markets to vertically integrate its business. As such, the Company has incurred losses as it expanded its operations. Management has put in place plans to increase the profitability of the business in fiscal year 2023 and beyond. In order to achieve profitable future operations, management has commercialized production from its recently expanded grower-processing facilities in Pennsylvania and Virginia, as well as implemented a cost-savings and efficiency optimization plan which includes, among other things, reduction in labor and packaging costs as well as operating efficiencies at the Company's retail and grower-processing facilities.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



As concluded in the 2022 Form 10-K, substantial doubt existed about the Company's ability to continue as a going concern, and, as a result of the above, substantial doubt continues to exist within the next twelve months from the date these financial statements are issued. Management intends to fund the Company's operations, capital expenditures and debt service with existing cash and cash equivalents on hand, cash generated from operations, including anticipated refunds from the Internal Revenue Service ("IRS") relating to employee retention credit claims, and, as needed, future financing (equity and/or debt) as well as the potential sales of non-core assets. The ability to continue as a going concern is dependent upon profitable future operations and positive cash flows from operations as well as future financing and/or sales of assets if necessary. There is no assurance that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

The unaudited consolidated financial statements contained herein have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounting Policies

The Company's significant accounting policies are described in Note 2 in the audited consolidated financial statements and notes thereto for the year ended December 31, 2022, which is included in the 2022 Form 10-K. Except as disclosed below, there have been no material changes to the Company's significant accounting policies.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:

	une 30, 2023 (unaudited)	December 31, 2022		
Cash and cash equivalents	\$ 26,784	\$	26,196	
Restricted cash - current (1)	3,128			
Restricted cash - non-current (1)	 2,150		950	
Cash, cash equivalents and restricted cash	\$ 32,062	\$	27,146	

As of June 30, 2023, restricted cash -current, and restricted cash - non-current, includes \$3,128 and \$1,200, respectively, relating to the Manassas Mortgage. Refer to Note 9 - Debt for more information.

Reclassification of Prior Year Presentation

Certain prior year amounts in the consolidated statements of cash flows have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported amounts of operating, investing and financing activities.

Recent Accounting Pronouncements

Accounting Standards Issued But Not Yet Adopted

In June 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-06 Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This ASU also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation in certain areas. The amendments in this ASU are effective for annual

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



and interim periods beginning after December 15, 2023, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.

In October 2021, the FASB issued ASU 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.* The FASB issued guidance requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree's financial statements (if the acquiree prepared financial statements in accordance with generally accepted accounting principles). The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. The FASB issued guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.

In March 2023, the FASB issued ASU 2023-01, *Leases (Topic 842): Common Control Arrangements*. The FASB issued guidance clarifies the accounting for leasehold improvements associated with common control leases, by requiring that leasehold improvements associated with common control leases be amortized by the lessee over the useful life of the leasehold improvements to the common control group (regardless of the lease term) as long as the lessee controls the use of the underlying asset through a lease. Additionally, leasehold improvements associated with common control leases should be accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023. The Company is in the process of evaluating the impact of this new guidance on its consolidated financial statements.

3. INVENTORY, NET

The components of inventory, net, are as follows:

	ne 30, 2023 naudited)	December 31, 2022		
Raw materials				
Cannabis plants	\$ 4,560	\$	4,347	
Harvested cannabis and packaging	8,847		9,052	
Total raw materials	13,407		13,399	
Work in process	5,399		7,845	
Finished goods	 21,974		13,845	
Total inventory, net	\$ 40,780	\$	35,089	

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



4. PREPAID EXPENSES AND OTHER CURRENT ASSETS

The components of prepaid expenses and other current assets are as follows:

	e 30, 2023 naudited)	December 31, 202		
Employee retention credit receivable	\$ 10,140	\$	<u>—</u>	
Prepaid expenses and deposits	3,523		3,409	
Other current assets	611		548	
Total prepaid expenses and other current assets	\$ 14,274	\$	3,957	

Employee retention credit ("ERC") receivable: The Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), passed in March 2020 and subsequently amended in 2021, allowed eligible employers to take credits on certain amounts of qualified wages if the Company experienced either a full or partial suspension of operations due to COVID related government orders. During the three months ended June 30, 2023, the Company, with guidance from a third-party specialist, determined it was entitled to ERC claims of \$10,140 for previous business interruptions related to COVID and filed for such claims with the IRS. The ERC claims, which will be recognized in the statements of operations and comprehensive income (loss) when the Company receives the refunds of such claims from the IRS, were recorded as deferred income in Accrued expenses and other current liabilities, with an offsetting receivable amount in Prepaid expenses and other current assets within the consolidated balance sheet as of June 30, 2023. Furthermore, on the statement of cash flow for the six months ended June 30, 2023, both the deferred income and related receivable are shown as non-cash items, and the impact of these two nets to zero.

5. PROPERTY, PLANT AND EQUIPMENT

The components of property, plant and equipment ("PPE") are as follows:

	June 30, 2023 (unaudited)	December 31, 2022		
Buildings and building components	\$ 91,775	\$ 80,697		
Land	14,301	14,085		
Leasehold improvements	45,104	43,472		
Machinery and equipment	29,595	27,615		
Furniture, fixtures and office equipment (including computer)	20,441	16,126		
Construction-in-process	852	20,086		
Property, plant and equipment, gross	202,068	202,081		
Less: Accumulated depreciation	(32,243)	(24,326)		
Property, plant and equipment, net	\$ 169,825	\$ 177,755		

Construction-in-process represents assets under construction for manufacturing and retail build-outs not yet ready for use.

PPE depreciation was \$4,483 and \$3,753 for the three months ended June 30, 2023 and 2022, respectively, and \$9,295 and \$6,300 for the six months ended June 30, 2023 and 2022, respectively. Interest expense capitalized to PPE totaled \$222 and \$1,303 for the three months ended June 30, 2023 and 2022, respectively, and \$410 and \$2,047 for the six months ended June 30, 2023 and 2022, respectively.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



6. ACQUISITIONS

Nature's Remedy

In connection with the Company's acquisition of Nature's Remedy of Massachusetts, Inc. and certain of its affiliates (collectively, "Nature's Remedy"), in September 2021 the Company agreed to issue up to an additional \$5,000 in Company SVS to Sammartino Investments LLC ("Sammartino") upon the occurrence or non-occurrence of certain events after the closing date. The payment of the contingent consideration depends on whether or not a competitor (as defined in the definitive acquisition documents) opens a competing dispensary within a certain radius of the Company's dispensary in Tyngsborough, Massachusetts during the period beginning on the 12-month anniversary of the closing date and ending on the 30-month anniversary of the closing date (the "Milestone Period"). On each monthly anniversary of the closing date during the Milestone Period (beginning on the 13-month anniversary of the closing date), Sammartino shall accrue \$278 worth of Company SVS (a "Monthly Milestone Accrual"). On the 18-month, 24-month and 30-month anniversary of the closing date (and provided a competitor has not opened a competing dispensary within a certain radius of the Company's dispensary in Tyngsborough, Massachusetts), Sammartino is entitled to be issued Company SVS in an amount equal to \$1,667 divided by a volume weighted average reference share price. As of December 31, 2022, the aggregate contingent consideration liability was \$4,793, of which \$3,398 was included as a short-term contingent consideration liability and \$1,395 was included in long-term contingent consideration liability.

In March 2023, the 18-month anniversary of the closing date occurred without a competitor opening a competing dispensary within a certain radius of the Company's dispensary in Tyngsborough, Massachusetts. Consequently, at June 30, 2023, \$2,500 of Monthly Milestone Accrual was classified as other current liabilities while the remaining liability of \$2,394 was included in short-term contingent consideration liability.

As discussed in greater detail in Note 18 - Commitments and Contingencies, on February 28, 2023, the Company informed Sammartino that Sammartino had breached several provisions of the Merger and Membership Interest Purchase Agreement between the Company, Sammartino and certain other parties thereto (as amended, the "MIPA") and pursuant to the terms of the MIPA the Company had elected to offset these damages against (among other things) all present and future Monthly Milestone Accruals (the "Sammartino Matter").

Purchase Price Allocations for 2022 Business Combinations

The purchase price accounting in connection with the acquisitions of "The Apothecarium" in Las Vegas, Nevada ("Apothecarium") and NuLeaf Inc., NuLeaf CLV Inc. and their subsidiaries (collectively, "NuLeaf") in March 2022 and April 2022, respectively, has been finalized as of March 31, 2023.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



7. OTHER NON-CURRENT ASSETS

The components of other non-current assets are as follows:

	June 30, 2023 (unaudited)	December 31, 2022
Operating lease assets (1)	\$ 24,427	\$ 16,244
Indemnification assets	9,011	8,198
Deposits and escrows - properties	1,665	1,637
Equity investment (2)	977	977
Net deferred tax assets	594	_
Deposits - equipment	530	484
Other	 67	703
Total other non-current assets	\$ 37,271	\$ 28,243

In June 2023, the Company performed a reassessment of its previously classified real estate finance leases, resulting in some leases being reclassified from finance to operating. Refer to Note 10 - Leases for more information.

8. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The components of accrued expenses and other current liabilities are as follows:

	ne 30, 2023 inaudited)	Decem	ber 31, 2022
Deferred income - ERC (1)	\$ 10,140	\$	_
Goods received not invoiced	7,534		11,620
Operating lease obligations	4,910		2,652
Accrued employee related expenses and liabilities	4,347		6,030
Accrued capital expenditures	3,058		5,603
Contingent consideration liabilities (2)	2,394		3,398
Accrued interest	3,419		2,388
Accrued sales and excise taxes	3,490		1,931
Deferred revenue (loyalty program)	1,495		1,870
Accrued professional and management fees	898		1,481
Other accrued expenses and current liabilities	8,172		9,356
Total	\$ 49,857	\$	46,329

⁽¹⁾ Refer to Note 4 - Prepaid Expenses and Other Current Assets for more information.

⁽²⁾ The Company owns a 23.08% ownership interest in PV Culver City, LLC ("PVLLC"). The Company does not have significant influence over, and the Company does not have the right to vote or participate in the management of PVLLC and therefore the investment is measured at its fair value. Refer to Note 19 - Financial Instruments for more information relating to the fair value of this equity investment as of June 30, 2023.

⁽²⁾ Refer to Note 6 - Acquisitions for more information.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



9. DEBT

The components of the Company's debt are as follows:

	Effective Interest Rate	Maturity Date		June 30, 2023	De	ecember 31, 2022
Principal amounts:						
Second Lien Notes	15%	December 2026	\$	74,330	\$	73,182
Acquisition Facility	15%	December 2024		65,000		65,000
Acquisition-related promissory notes payable	8% - 23%	August 2024 - April 2027		35,716		35,716
Mortgage loans	6% - 9%	January 2027 - April 2028		29,552		7,770
Total debt subject to scheduled repayments				204,598		181,668
Promissory notes payable to Sammartino (1)	11%	September 2024 - September 2026		21,500		21,500
Jushi Europe debt ⁽²⁾	n/a	March 2022	_	3,254		3,190
Total debt				229,352		206,358
Less: debt issuance costs and original issue discounts			_	(15,920)		(17,096)
Total debt, net			\$	213,432	\$	189,262
Debt, net - current portion			\$	14,791	\$	8,704
Debt, net - non-current portion			\$	198,641	\$	180,558

This amount is related to the promissory notes issued to Sammartino in connection with the acquisition of Nature's Remedy in September 2021. Any repayment of principal and interest are currently on hold until the resolution of the Sammartino Matter. Refer to Note 18 - Commitments and Contingencies for more information.

Second Lien Notes

In March 2023, the Company, one of its wholly subsidiaries (JGMT, LLC) and the Company's Chief Executive Officer and Chairman of the Board of Directors ("CEO") entered into an amendment to his existing employment agreement (the "Amendment") pursuant to which the CEO agreed to receive the \$750 annual cash bonus that would otherwise have been paid to him in the following alternative form: (i) a lump sum cash payment in the amount of \$250, which was paid on March 15, 2023, (ii) \$750 aggregate principal amount of 12% second lien notes ("Second Lien Notes") due December 7, 2026, which was issued on March 15, 2023, and (iii) fully-detached warrants to purchase up to approximately \$375 worth of the Company's SVS ("Warrants"), with such Warrants to be priced and issued as soon as practicable in accordance with US and Canadian securities laws. The Warrants, when issued, will have an exercise price per subordinate voting share equal to the greater of: (a) a twenty-five percent (25%) premium to the volume-weighted average price per share of the Company's subordinate voting shares on the Canadian Securities Exchange (converted into U.S. Dollars at an exchange rate determined by the Company in good faith) over the trailing ten (10) trading day period prior to the date the Warrants are issued, and (b) the fair market value of the Company's subordinate voting shares on the Canadian Securities Exchange (converted into U.S. Dollars at an exchange rate determined by the Company in good faith) on the date the Warrants are issued. As of June 30, 2023, the fair value of the Warrants to be priced and issued was estimated to be \$148, which was recorded as additional debt discount to the Second Lien Notes with a corresponding offset to Accrued expenses and other current liabilities. The current estimated fair value of the Warrants will be adjusted when the Warrants are priced and issued.

On February 16, 2022, Jushi Europe SA, a company organized under the laws of Switzerland ("Jushi Europe"), filed a notice of over-indebtedness with the Swiss courts. Then, the Swiss courts declared Jushi Europe's bankruptcy on May 19, 2022. As a result, Jushi Europe updated its corporate name to Jushi Europe SA in liquidation, which is still on-going. This debt balance will be adjusted, including the extinguishment of any outstanding debt, upon the final liquidation of Jushi Europe. Refer to Note 17 - Related Party Transactions for more information.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



In June 2023, the Company amended its Second Lien Notes to modify the Change of Control provisions and make other changes. The consideration paid by the Company for the amendment was a repricing of the related outstanding warrants to purchase SVS of the Company from an exercise price of \$2.086 per warrant to \$1.00 per warrant. In addition to the repricing of the warrants, the respective warrant agreements were amended and resulted in a change in accounting classification of the respective warrants from liability to equity. The estimated value of the consideration of \$1,341 was determined based on the incremental change in the fair value of the warrants before and after repricing. The consideration was recorded as additional debt discount to the Second Lien Notes with a corresponding offset to Paid-in capital. Refer to Note 11 - Derivative Liabilities for more information.

Mortgage loans

Arlington Mortgage

In December 2021, the Company entered into a \$6,900 mortgage loan agreement (the "Arlington Mortgage"), which is principally secured by the Company's retail property in Arlington, Virginia. The Arlington Mortgage bears a fixed interest rate of 5.875% per annum, payable monthly, and will mature in January 2027. As of December 31, 2022, the Company had drawn down \$5,000, and the remaining \$1,900 was drawn down in January 2023.

Dickson City Mortgage

In July 2022, the Company entered into a \$2,800 mortgage loan agreement (the "Dickson City Mortgage"), which is principally secured by the Company's retail property in Dickson City, Pennsylvania. The Dickson City Mortgage matures in July 2027 and bears interest at a variable rate equal to prime rate plus 2%. The interest rate as of June 30, 2023 was 10.25%.

Manassas Mortgage

In April 2023, the Company entered into a \$20,000 mortgage loan agreement (the "Manassas Mortgage"), which is principally secured by the Company's cultivation and manufacturing facility located in Manassas, Virginia. The Manassas Mortgage bears interest of 8.625% per annum as of June 30, 2023, payable monthly, and will mature in April 2028. The interest rate is variable and determined based on the 30-day average secured overnight financing rate plus 3.55%, with a floor rate of not less than 8.25%.

Financial covenants

Acquisition Facility

The Senior Secured Credit Facility (the "Acquisition Facility") contains certain financial and other covenants with which the Company is required to comply. On May 10, 2023, the Company was non-compliant with an affirmative covenant relating to a minimum cash deposit requirement in a specified bank account. The Company received a waiver for this instance on May 11, 2023. As of June 30, 2023, the Company was in compliance with its financial covenants related to (i) minimum unrestricted cash and cash equivalents balance requirement and (ii) minimum quarterly revenue requirement.

Mortgage loans

The Company's three mortgage loan agreements contain certain financial and other covenants with which the Company is required to comply. As of June 30, 2023, the Company was in compliance with all financial covenants contained in each of the mortgage loan agreements.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



Annual Maturities

As of June 30, 2023, aggregate future scheduled repayments of the Company's debt are as follows:

	Remain the	nder of year	2024	2025	2026	2027	Thereafter	Total
Second Lien Notes	\$	— \$	— \$	— \$	74,330 \$	_ 5	- \$	74,330
Acquisition Facility		4,875	60,125			_		65,000
Acquisition-related promissory notes payable		3,448	5,885	1,970	1,971	22,442	_	35,716
Mortgage loans		101	485	658	669	9,399	18,240	29,552
Total debt subject to scheduled repayments	\$	8,424 \$	66,495 \$	2,628 \$	76,970 \$	31,841	\$ 18,240 \$	204,598

The above table excludes the contractual maturities of the Company's (i) promissory notes payable to Sammartino and (ii) Jushi Europe debt, as the repayments of these two debts are contingent on the resolution of the Sammartino Matter and completion of the liquidation of Jushi Europe, respectively. Refer to Note 18 - Commitments and Contingencies and Note 17 - Related Party Transactions for more information. Specifically, the contractual maturities of (i) the promissory notes payable to Sammartino are as follows: \$16,500 in 2024 and \$5,000 in 2026 and (ii) Jushi Europe debt was March 2022.

Interest Expense

Interest expense, net is comprised of the following:

		Three Months	End	ed June 30,	Six Months Ended June 30,			
	2023 2022				2023		2022	
Interest expense								
Interest and accretion - 10% Senior Notes	\$		\$	5,838	\$ —	\$	11,236	
Interest and accretion - Second Lien Notes		2,584			4,928			
Interest and accretion - Finance lease liabilities		2,598		3,013	4,947		5,914	
Interest and accretion - Promissory notes		1,542		1,347	3,078		2,084	
Interest and accretion - Acquisition Facility		2,671		1,854	4,967		3,294	
Interest and accretion - Mortgage loans and other financing activities		625		221	810		620	
Capitalized interest		(222)		(1,303)	(410)		(2,047)	
Total interest expense		9,798		10,970	18,320		21,101	
Interest income		(8)		(23)	(10)		(38)	
Total interest expense, net	\$	9,790	\$	10,947	\$ 18,310	\$	21,063	

10. LEASES

The Company leases certain business facilities for corporate, retail and cultivation operations from third parties under lease agreements that specify minimum rentals. In addition, the Company leases certain equipment for use in cultivation and extraction activities. The Company determines whether a contract is or contains a lease at the inception of the contract. In June 2023, the Company performed a reassessment of its previously classified real estate finance leases due to changing demographics and business environment. This reassessment resulted in the removal of certain option renewal periods contained in the leases as the Company is no longer reasonably certain to exercise these option renewal periods. As a result of the reassessment, the classification of some leases were changed from finance to operating. Additionally, the impact of the reassessment was an aggregate decrease in finance lease obligations and related right-of-use ("ROU") assets of \$45,768 and \$42,349, respectively, and an aggregate increase in operating lease obligations and related ROU assets of \$8,691 and \$5,271, respectively. In connection with the change from finance to operating lease, the Company's

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



depreciation and interest expense related to ROU assets will be lower after the change, and the rent expense will be higher. The expiry dates of the leases, including reasonably certain estimated renewal periods, are between 2023 and 2043. The Company's lease agreements do not contain any material residual value guarantees or material restrictive covenants.

The following table provides the components of lease cost recognized in the consolidated statements of operations and comprehensive income (loss) for the periods presented.

	Three Months Ended June 30,					Six Months E	nded	ded June 30,		
		2023		2022	2023			2022		
Finance lease cost:										
Amortization of lease assets	\$	1,469	\$	1,261	\$	3,059	\$	2,403		
Interest on lease liabilities		2,598		3,013		4,947		5,914		
Total finance lease cost	•	4,067		4,274		8,006		8,317		
Operating lease cost		915		914		1,648		1,800		
Variable lease cost		20		89		86		182		
Total lease cost	\$	5,002	\$	5,277	\$	9,740	\$	10,299		

Other information related to operating and finance leases as of the balance sheet dates presented are as follows:

	June 30	, 2023			
	(unauc	lited)	December	31, 2022	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases	
Weighted average discount rate	16.07 %	13.09 %	11.23 %	11.51 %	
Weighted average remaining lease term (in years)	17.0	12.7	22.7	14.1	

The maturities of the contractual undiscounted lease liabilities as of June 30, 2023 are as follows:

	F	inance Leases	_(Operating Leases
Remainder of year	\$	4,491	\$	2,427
2024		10,653		5,667
2025		10,517		5,581
2026		10,409		5,319
2027		9,950		5,161
Thereafter		158,127		43,157
Total lease payments		204,147		67,312
Less: Imputed interest		(142,662)		(36,946)
Total present value of minimum lease payments	\$	61,485	\$	30,366
Lease liabilities - current portion	\$	8,786	\$	4,910
Lease liabilities - non-current	\$	52,699	\$	25,456

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



11. DERIVATIVE LIABILITIES

The following table summarizes the change in the Company's derivative liabilities for the six months ended June 30, 2023.

	Derivative pilities ⁽¹⁾
Balance as of January 1, 2023	\$ 14,134
Fair value changes	(9,120)
Reclassification to equity	(2,050)
Down-round changes	143
Balance as of June 30, 2023	\$ 3,107

Refer to Note 12 - Equity for the change in number of warrants during the six months ended June 30, 2023.

The Company's derivative liabilities are primarily comprised of derivative warrants ("Derivative Warrants"). These are warrants to purchase SVS of the Company, and were previously issued in connection with the Company's Second Lien Notes and its 10% senior secured notes (the "Senior Notes"). As discussed in Note 9 - Debt, in June 2023, the Company amended the warrant agreements, previously issued with the Second Lien Notes, to decrease the warrant exercise price of \$2.086 per warrant to \$1.00 per warrant for 17,512,280 warrants as well as certain other sections of the warrant agreement, which resulted in a change in accounting classification of the respective warrants from liability to equity. As a result of the change in classification of the warrants, the Company recorded a decrease in derivative liability of \$2,050, with a corresponding increase in paid-in capital. The aforementioned warrant repricing triggered certain down-round provisions on some of the outstanding warrants previously issued with the Senior Notes. Accordingly, the Company changed the warrant exercise price of \$1.25 per warrant to \$1.00 per warrant for 5,890,922 warrants, and recorded the incremental change of \$143 in the fair value of such warrants before and after repricing as additional derivative liabilities with a corresponding offset to Other income (expense) since the Senior Notes were previously extinguished.

The Derivative Warrants may be net share settled. As of June 30, 2023, there were 37,862,922 Derivative Warrants outstanding, which consisted of (i) 29,972,000 warrants with exercise price of \$1.25 per warrant and expiration date in December 2024, (ii) 5,890,922 warrants with exercise price of \$1.00 per warrant and expiration date of December 2024, and (iii) 2,000,000 warrants with an exercise price of \$2.086 per warrant and expiration date in December 2026. As of December 31, 2022, there were 55,375,202 Derivative Warrants outstanding, which consisted of (i) 35,862,922 warrants with exercise price of \$1.25 per warrant and expiration date in December 2024, and (ii) 19,512,280 warrants with an exercise price of \$2.086 per warrant and expiration date in December 2026.

Derivative Warrants are considered derivative financial liabilities measured at fair value with all gains or losses recognized in profit or loss as the settlement amount for the Derivative Warrants may be adjusted during certain periods for variables that are not inputs to standard pricing models for forward or option equity contracts, i.e., the "fixed for fixed" criteria under ASC 815-40. The estimated fair value of the Derivative Warrants is measured at the end of each reporting period and an adjustment is reflected in fair value changes in derivatives in the consolidated statements of operations and comprehensive income (loss). These are Level 3 recurring fair value measurements. The estimated fair value of the Derivative Warrants was determined using the Black-Scholes model with stock price based on the OTCQX closing price of the Derivative Warrants issue date as of June 30, 2023 and December 31, 2022.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



The assumptions used in the fair value calculations as of the balance sheet dates presented include the following:

	June 30, 2023 (unaudited)	December 31, 2022
Stock price	\$0.48	\$0.76
Risk-free annual interest rate	4.24% - 5.15%	3.99% - 4.11%
Range of estimated possible exercise price	\$1.00 - \$2.086	\$1.25 - \$2.086
Weighted average volatility	84%	79%
Remaining life	1.48 years - 3.44 years	1.98 years - 3.96 years
Forfeiture rate	0%	0%
Expected annual dividend yield	0%	0%

Volatility was estimated by using a weighting of the Company's historical volatility and the average historical volatility of comparable companies from a representative peer group of publicly traded cannabis companies. The risk-free interest rate for the expected life of the Derivative Warrants was based on the yield available on government benchmark bonds with an approximate equivalent remaining term. The expected life is based on the contractual term. If any of the assumptions used in the calculation were to increase or decrease, this could result in a material or significant increase or decrease in the estimated fair value of the derivative liability. For example, the following table illustrates an increase or decrease in certain significant assumptions as of the balance sheet dates:

			As o	of June 30, 2023	i						
	(unaudited)						As	of l	December 31, 20	22	
		Input	Е	ffect of 10% Increase	F	Effect of 10% Decrease	Input	I	Effect of 10% Increase	F	Effect of 10% Decrease
Stock price	\$	0.48	\$	724	\$	(658)	\$ 0.76	\$	2,529	\$	(2,396)
Volatility		84 %		736		(706)	79 %		2,070		(2,121)

12. EQUITY

Authorized, Issued and Outstanding

The authorized share capital of the Company consists of an unlimited number of SVS, Multiple Voting Shares, Super Voting Shares, and Preferred Shares. As of June 30, 2023, the Company had 196,633,371 SVS issued and outstanding and no Multiple Voting Shares, Super Voting Shares or Preferred Shares issued and outstanding.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



Warrants

Each warrant entitles the holder to purchase one SVS. Certain warrants may be net share settled. The following table summarizes the status of warrants and related transactions:

	Non-Derivative (Equity) Warrants	Derivative Liabilities Warrants ⁽¹⁾	Total Number of Warrants	ighted - Average Exercise Price
Balance as of January 1, 2023	30,673,635	55,375,202	86,048,837	\$ 1.40
Granted	300,000		300,000	\$ 0.48
Cancelled/forfeited/expired	(100,000)		(100,000)	\$ 1.47
Reclassification	17,512,280	(17,512,280)		\$
Balance as of June 30, 2023	48,385,915	37,862,922	86,248,837	\$ 1.16
Exercisable as of June 30, 2023	45,985,915	37,862,922	83,848,837	\$ 1.14

In June 2023, 5,890,000 warrants were repriced from \$1.25 to \$1.00. Additionally, 17,512,280 warrants were reclassified from derivative liability warrants to non-derivative (equity) warrants and repriced from \$2.086 to \$1.00. Refer to Note 11 - Derivative Liabilities for additional information.

Share-based payment award plans

Plan summary and description

Under the Company's 2019 Equity Incentive Plan, as amended, (the "2019 Plan"), non-transferable options to purchase SVS and restricted SVS of the Company may be issued to directors, officers, employees, or consultants of the Company. The 2019 Plan authorizes the issuance of up to 15% (plus an additional 2% inducements for hiring employees and senior management) of the number of outstanding shares of common stock (of all classes) of the Company (the "Share Reserve"). Incentive stock options are limited to the Share Reserve, and the maximum number of incentive awards available for issuance under the 2019 Plan, including additional awards available for certain new hires, was 3,575,590 as of June 30, 2023.

Stock Options

The stock options issued by the Company are options to purchase SVS of the Company. All stock options issued have been issued to directors and employees under the Company's 2019 Plan. Such options generally expire in ten years from the date of grant and generally vest ratably over three years from the grant date. The options generally may be net share settled. The following table summarizes the status of stock options and related transactions:

	Number of Stock Options	Per	d-Average Share ise Price
Issued and Outstanding as of January 1, 2023	30,752,259	\$	2.58
Granted	3,827,500	\$	0.51
Cancelled/forfeited/expired	(4,384,005)	\$	2.76
Issued and Outstanding as of June 30, 2023	30,195,754	\$	2.29
Exercisable as of June 30, 2023	17,131,076	\$	2.51

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



The fair value of the stock options granted was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of grant:

	Six Months E	nded June 30,
	2023	2022
Weighted average stock price	\$0.51	\$2.78
Weighted average expected stock price volatility	76.9%	74.5%
Expected annual dividend yield	0%	0%
Weighted average expected life	6.0 years	6.2 years
Weighted average risk-free annual interest rate	3.6%	2.8%
Weighted average grant date fair value	\$0.34	\$1.40

Restricted Stock

The Company grants restricted SVS to independent directors, management, former owners of acquired businesses or assets, and to consultants and other employees. The restricted SVS are included in the issued and outstanding SVS, and the fair value of the restricted stock granted was estimated based on the SVS price at grant date. The following table summarizes the status of restricted stock and related transactions:

	Number of Restricted Subordinate Voting Shares
Unvested restricted stock as of January 1, 2023	1,156,319
Cancelled/forfeited	(53,001)
Vested and Released	(1,097,823)
Unvested restricted stock as of June 30, 2023	5,495

Generally, restricted stock awards will vest either one-third on each anniversary of service from the vesting start date or will be fully vested on the completion of one year of full service from the vesting start date, depending on the award.

Share-based compensation cost

The components of share-based compensation expense are as follows:

		Three Months	d June 30,	 Six Months Ended June 30,			
	2023 2022			2022	2023		2022
Stock options	\$	1,862	\$	3,955	\$ 3,458	\$	9,799
Restricted stock		93		446	293		1,279
Warrants		408		283	923		570
Total share-based compensation expense	\$	2,363	\$	4,684	\$ 4,674	\$	11,648

As of June 30, 2023, the Company had \$9,480 of unrecognized share-based compensation cost related to unvested stock options, restricted stock and warrants, which is expected to be recognized as share-based compensation cost over a weighted average period of 1.7 years.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



13. EARNINGS (LOSS) PER SHARE

The reconciliations of the net income (loss) and the weighted average number of shares used in the computations of basic and diluted earnings (loss) per share attributable to Jushi shareholders are as follows:

	Three Months Ended June 30,					Six Months Ended June 30,				
	2023 2022				2023		2022			
Numerator:										
Net income (loss) and comprehensive income (loss) attributable to Jushi shareholders	\$	(14,036)	\$	12,066	\$	(26,476)	\$	(7,691)		
Dilutive effect of net income from derivative warrants liability		_		(42,572)		_		(56,881)		
Less undistributed net income (loss) for participating securities				(197)		_		140		
Net income (loss) and comprehensive income (loss) attributable to Jushi shareholders - diluted	\$	(14,036)	\$	(30,703)	\$	(26,476)	\$	(64,432)		
Denominator:										
Weighted-average shares of common stock - basic		194,756,391		190,870,572		194,405,562		187,147,856		
Dilutive effect of derivative warrants				14,826,581		_		20,890,427		
Weighted-average shares of common stock - diluted		194,756,391		205,697,153		194,405,562		208,038,283		
Earnings (loss) per common share attributable to Jushi shareholders:										
Basic	\$	(0.07)	\$	0.06	\$	(0.14)	\$	(0.04)		
Diluted	\$	(0.07)	\$	(0.15)	\$	(0.14)	\$	(0.31)		

The following table summarizes weighted average instruments that may, in the future, have a dilutive effect on earnings (loss) per share, but were excluded from consideration in the computation of diluted net income (loss) per share for the three and six months ended June 30, 2023 and 2022, because the impact of including them would have been anti-dilutive:

	Three Months I	Ended June 30,	Six Months E	nded June 30,
	2023	2022	2023	2022
Stock options	29,248,553	20,604,848	28,941,749	20,654,797
Warrants (derivative liabilities and equity)	86,097,189	29,448,567	86,043,865	29,420,800
Unvested restricted stock awards	376,980	1,657,307	746,843	2,631,487
Convertible promissory notes		910,000		910,000
	115,722,722	52,620,722	115,732,457	53,617,084

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



14. REVENUE

The Company has three revenue streams: (i) retail, (ii) wholesale and (iii) other. The Company's retail revenues are comprised of cannabis sales from its dispensaries. The Company's wholesale revenues are comprised of cannabis sales to its wholesale customers for resale through their dispensaries. The Company's other operations primarily include the Company's hemp/cannabidiol ("CBD") retail operations which were discontinued in 2022. Any intercompany revenue and costs are eliminated to arrive at consolidated totals.

The following table summarizes the Company's revenue from external customers, disaggregated by revenue stream:

	Three Months Ended June 30,					Six Months E	Six Months Ended June 30,			
		2023		2022		2023		2022		
Retail	\$	59,615	\$	67,276	\$	121,926	\$	125,230		
Wholesale		6,810		5,467		14,372		9,316		
Other				14		_		99		
Total revenue, net	\$	66,425	\$	72,757	\$	136,298	\$	134,645		

15. OPERATING EXPENSES

The major components of operating expenses are as follows:

		Three Months	Ended	Six Months Ended June 30,				
	2023			2022		2023	2022	
Salaries, wages and employee related expenses	\$	13,784	\$	18,593	\$	30,588	\$	35,930
Share-based compensation expense		2,363		4,684		4,674		11,648
Rent and related expenses		2,504		3,404		5,397		6,493
Depreciation and amortization expense		1,577		2,865		4,240		5,121
Professional fees and legal expenses		2,321		2,803		4,646		5,509
Other expenses (1)		4,605		6,396		10,061		11,757
Total operating expenses	\$	27,154	\$	38,745	\$	59,606	\$	76,458

Other expenses are primarily comprised of marketing and selling expenses, insurance costs, administrative and application fees, software and technology costs, travel, entertainment and conferences and other.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



16. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three and six months ended June 30, 2023 and 2022:

	 Three Months	l June 30,		Six Months Ended June 30,					
	2023		2022		2023	2022			
Income (loss) before income tax	\$ (5,490)	\$	19,776	\$	(7,782)	\$	5,070		
Income tax expense	\$ 8,546	\$	7,710	\$	18,694	\$	12,761		
Effective income tax rate	(155.7)%)	39.0 %	o	(240.2)%	ı	251.7 %		

The Company has computed its provision for income taxes based on the actual effective rate for the six months ended June 30, 2023 and 2022 as the Company believes this is the best estimate for the annual effective tax rate. Therefore, the Company's effective income tax rates for the three and six months ended June 30, 2023 and 2022 are not indicative of the effective income tax rate for each respective fiscal year of 2023 and 2022. The Company's effective income tax rate is significantly higher than the statutory income tax rates due in part to (i) disallowed expenses under U.S. Internal Revenue Code of 1986, as amended ("IRC"), Section 280E, (ii) change in uncertain tax positions, (iii) fair value change of derivatives, (iv) interest and penalties accrual for tax liabilities, and (v) state income taxes.

Due to its cannabis operations, the Company is subject to the limitation of IRC Section 280E under which the Company is only allowed to deduct "costs of goods sold". This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E. Therefore, the effective tax rate can be highly variable and may not necessarily correlate with pre-tax income which provides for effective tax rates that are well in excess of statutory tax rates.

The Company's tax returns for the year 2021 and prior benefited from not applying IRC Section 280E to certain entities of the consolidated group either due to the entity not yet starting operations or because the entity had a separate trade or business that was not medical or recreational cannabis operations. The Company determined that it is not more likely than not these tax positions would be sustained under examination. As a result, the Company has an uncertain tax liability of \$60,491 and \$57,200 as of June 30, 2023 and December 31, 2022, respectively, inclusive of interest and penalties, which is included in income tax liabilities - non-current in the consolidated balance sheets. Additionally, there are unrecognized deferred tax benefits of \$3,414 and \$3,412 as of June 30, 2023 and December 31, 2022, respectively. The Company does not expect the unrecognized tax benefits will materially increase or decrease within the next 12 months.

The amount of interest and penalties related to outstanding income tax liabilities recorded by the Company during the three and six months ended June 30, 2023 was \$644 and \$1,533, respectively. The amount of interest and penalties related to outstanding income tax liabilities recorded by the Company during the three and six months ended June 30, 2022 was not material. Additionally, the Company's income tax payable of \$32,575 and \$19,921 as of June 30, 2023 and December 31, 2022, respectively, included deferral of certain 2023 and 2022 estimated income tax payments.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



17. RELATED PARTY TRANSACTIONS

The Company had the following related party transactions:

	Three Months Ended June 30,		 Six Months E	Months Ended June 30,			As of				
		2023		2022	2023		2022		ne 30, 2023 unaudited)	De	cember 31, 2022
Nature of transaction		Related Par	ty E	Expense	Related Par	rty I	Expense		Related Par	ty P	ayable
10% Senior Notes - interest expense and principal amount	\$	_	\$	(8)	\$ _	\$	(17)	\$	_	\$	_
12% Second Lien Notes - interest expense and principal amount ⁽¹⁾	\$	(563)	\$	_	\$ (1,084)	\$	_	\$	(18,526)	\$	(17,491)
Other debt (2)	\$	_	\$	_	\$ _	\$	_	\$	(3,254)	\$	(3,189)

For the periods ended June 30, 2023 and December 31, 2022, the Second Lien Notes payable and the related interest expense includes amounts related to a director as well as a significant investor.

18. COMMITMENTS AND CONTINGENCIES

Contingencies

Although the possession, cultivation and distribution of cannabis for medical and recreational use is permitted in certain states, cannabis is classified as a Schedule-I controlled substance under the U.S. Controlled Substances Act and its use remains a violation of federal law. The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management believes that the Company is in material compliance with applicable local and state regulations as of June 30, 2023, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company could be subject to regulatory fines, penalties or restrictions at any time. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in the Company's inability to proceed with the Company's business plans. In addition, the Company's assets, including real property, cash and cash equivalents, equipment, inventory and other goods, could be subject to asset forfeiture because cannabis is still federally illegal.

Refer to Note 16 - Income Taxes for certain tax-related contingencies.

Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2023, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company's financial results. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

MJ Market matter

On March 31, 2023, MJ's Market ("MJ's"), Inc. filed a complaint in federal district court in Massachusetts adverse to Jushi Holdings, Inc. and the following of its subsidiaries, including Jushi MA, Inc., Jushi Inc. and Nature's Remedy of Massachusetts ("collectively "Jushi"), as well as the former owners and affiliates of Nature's Remedy of Massachusetts ("Complaint"). The Complaint centrally claims that the structure of the Nature's Remedy of Massachusetts transaction providing for increased purchase price consideration if there is no competing dispensary within 2,500 foot radius by

Other debt relates to Jushi Europe. On February 16, 2022, Jushi Europe filed a notice of over-indebtedness with the Swiss courts. Then, the Swiss courts declared Jushi Europe's bankruptcy on May 19, 2022. As a result, Jushi Europe updated its corporate name to Jushi Europe SA in liquidation, which is still on-going.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



certain time periods, and the Company's filing with the Massachusetts Superior Court an appeal of the Town of Tyngsborough's decision to approve MJ's facility in contradiction of its own zoning bylaws are violations of the Sherman Antitrust Act, Massachusetts Antitrust Act, and Massachusetts Consumer Protection Act, as well as interference with contractual relations and abuse of process. MJ is seeking legal and equitable remedies including compensatory and other damages. The Company vehemently denies such allegations, and is vigorously defending against the Complaint.

Sammartino Matter

On February 28, 2023, the Company informed Sammartino, the former owner of Nature's Remedy and certain of its affiliates, that Sammartino had breached several provisions of the MIPA and/or fraudulently induced the Company to enter into, and not terminate, the MIPA. As a consequence of these breaches and the fraudulent inducement, the Company informed Sammartino that the Company had incurred significant damages, and pursuant to the terms of the MIPA the Company had elected to offset these damages against certain promissory notes and shares the Company was to pay and issue, respectively, to Sammartino, and that Sammartino would be required to pay the remainder in cash. On March 13, 2023, Sammartino responded to the Company by alleging various procedural deficiencies with the Company's claim and provided the Company with a notice that the Company was in default of the MIPA for failing to issue certain shares of the Company to Sammartino. On March 21, 2023, Sammartino sent a second notice that the Company was in default of the promissory notes for failing to pay interest pursuant to their specified schedule. On March 23, 2023, the Company sent a second letter to Sammartino disputing each procedural deficiency claimed by Sammartino and disputing that the Company is in default of the MIPA or the promissory notes and that it properly followed the terms of the various agreements in electing to set off the damages.

Pacific Collective matter

On October 24, 2022, Pacific Collective, LLC ("Pacific Collective") filed a complaint in state court in California against Jushi subsidiaries TGS CC Ventures, LLC ("TGS"), and Jushi Inc. Pacific Collective alleges that the Jushi subsidiaries breached a commercial property lease and lease guaranty and that Pacific Collective is entitled to recover in excess of \$20,000 in damages. TGS lawfully rescinded the lease based on Pacific Collective's failure to purchase the property that was the subject of the lease and to construct and deliver the building contemplated by the lease, and is of the position that no damages are owed to Pacific Collective.

Commitments

In addition to the contractual obligations outlined in Note 9 - Debt and Note 10 - Leases, the Company has the following commitments as of June 30, 2023 related to property and construction.

Property and Construction Commitments

In connection with various license applications, the Company may enter into conditional leases or other property commitments which will be executed if the Company is successful in obtaining the applicable license and/or resolving other contingencies related to the license or application.

In addition, the Company expects to incur capital expenditures for leasehold improvements and construction of buildouts of certain locations, including for properties for which the lease is conditional on obtaining the applicable related license or for which other contingencies exist. If the Company were to be unsuccessful in obtaining a particular license or certain other conditions are not met, the previously capitalized improvements and buildouts relating to that license may need to be expensed in future periods in the statements of operations and comprehensive income (loss).

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



19. FINANCIAL INSTRUMENTS

The following table sets forth the Company's financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy:

	ne 30, 2023 naudited)	December 31, 2022		
Financial assets: (1)				
Equity investment	\$ 977	\$	977	
Total financial assets	\$ 977	\$	977	
Financial liabilities: (1)				
Derivative liabilities (2)	\$ 3,107	\$	14,134	
Contingent consideration liabilities (3)	 2,394		4,793	
Total financial liabilities	\$ 5,501	\$	18,927	

⁽¹⁾ The Company has no financial assets or liabilities in Level 1 or 2 within the fair value hierarchy as of June 30, 2023 and December 31, 2022, and there were no transfers between hierarchy levels during the six months ended June 30, 2023 or year ended December 31, 2022.

The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and certain accrued expenses, and certain other assets and liabilities held at amortized cost, approximate their fair values due to the short-term nature of these instruments. The equity investment approximates its fair value at June 30, 2023 and December 31, 2022. The fair value of the Company's debt approximates their fair values as of June 30, 2023 and December 31, 2022 as their effective interest rates are consistent with market rates.

⁽²⁾ Refer to Note 11 - Derivative Liabilities.

⁽³⁾ Refer to Note 6 - Acquisitions.